May 19, 2009 - Volcano Corp. yesterday announced an exclusive worldwide distribution agreement to initiate the formal launch of the Xtract thrombus aspiration catheter, manufactured by Lumen Biomedical.
The Xtract thrombus aspiration catheter is available for immediate sale in the U.S. and Europe. This marks Volcano’s entry into what we believe is a $70 million aspiration market. The Xtract thrombus aspiration catheter has been cleared by the FDA and is CE marked for use in coronary vessels, as well as some peripheral vascular applications. The device incorporates three unique design attributes that enhance its performance. These include a single lumen design to maximize cross-sectional area, and in turn, thrombus suction; a circular, right angle tip for close-up access to clots; and a curved, directional tip to enable full sweep of the vessel. These unique design features enable physicians to offer a truly new approach for thrombus aspiration.
“We have been using the Xtract catheter at Jackson Memorial Hospital since October 2008,” said Jim Margolis, director, cardiovascular research and education, Miami International Cardiology Consultants. “In my view, compared to other thrombectomy catheters I have used, this device is in a generation of its own. It tracks better, removes an order of magnitude more debris, and resists kinking. Because of its ease of use and effectiveness, some of us have begun using it on non-STEMI patients as well as STEMI patients.”
The use of thrombus aspiration in AMI patients has increased dramatically, fueled by the positive one-year results of the TAPAS study, which was published in the New England Journal of Medicine.
For more information: www.volcanocorp.com
April 03, 2024 
